Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
October 29, 2025 | HEOR, ISPOR Europe, Market Access, Pricing, US policy, access and pricing, ispor, isporeurope, mfn, most-favoured nation, reimbursement
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10 poster presentations, and the opportunity to try EVID AI, a fast track to literature-based research and evidence synthesis.
With a drinks reception at 5pm on the Monday, the opportunity to grab a free Scottish-themed minifigure, and experts available at the booth at all times, the company warmly invites all attendees to stop by booth 212 for a chat.
HEOR THEATER
MFN Pricing: “More Fun to Navigate” – A European Roadmap to Success
At 12.15pm in Theater 1 on Tuesday 11th November, Tim Wright, EVP, Access & Pricing, Genesis Research Group, will be delivering a presentation on most favored nation (MFN) pricing. Anyone responsible for pricing, market access, early commercial strategy, policy, or HEOR, will find great value in the content.
Most-Favored Nation (MFN) pricing is characterized by uncertainty, particularly regarding how the Administration will steer it through Congress. However, we cannot wait for the legislative process to complete—doing nothing is not an option. Tim Wright, EVP at Genesis Research Group, with 30 years of in-house and consulting experience, will provide a practical walk-through on how to plan for success, including key milestones and challenges along the way.
During the session, Tim will cover essential steps in establishing the US anchor price, including the role of value-based pricing, the importance of setting an early economically justifiable price, and the pros and cons of different US price options. He will then “fly across the Atlantic” to show how these planning steps can positively influence European strategic pricing and, importantly, what options manufacturers have to minimize price erosion risks from subsequent approvals.
By the end of the session, attendees will have:
- A roadmap to help guide them
- through the uncharted territory of Most-Favored Nation pricing.
- A clear understanding of the implications for both biotechs and large pharma.
TRY EVID AI FOR YOURSELF!
Genesis Research Group will also be providing visitors to its booth the opportunity to try EVID AI for themselves. EVID AI is an AI-powered platform for finding, reviewing, and understanding literature-based evidence. If you have too many questions and not enough time, EVID AI allows you to quickly find the most relevant literature, receive AI-generated research summaries, and access to reliable, up-to-date sources.
Visitors will be able to give the platform a try by themselves or they can ask one of Genesis’s evidence synthesis experts for a guided tour.
GRAB A FREE MINIFIGURE!
Visit booth 212 to secure a free minifigure, custom-designed for ISPOR Europe! Choose from a variety of skin tones, hair and facial expressions.
10 SCIENTIFIC CONTRIBUTIONS
Genesis Research Group is proud to have contributed to 10 posters to the conference, including two posters recognized by ISPOR EU as among the top 5% of submissions. See the timetable below or visit ISPOR Europe’s website for full details.
DRINKS RECEPTION
Attendees will also be able to connect with the Genesis Research Group team on an informal basis. Complimentary drinks and canapés will be served from 5pm on Monday 10th November.
Schedule a meeting with the Genesis team
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research and Clinical Outcomes Solutions announce innovative partnership
International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...
Genesis Research Acquires Market Access Transformation
Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...
GHO Capital Acquires Genesis Research
GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes...
Genesis Research: What is EVID AI?
Genesis Research Announces Significant Enhancements to EVID AI, the World's Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches